Enterra® Therapy Partnering for Gastric Health

Slides:



Advertisements
Similar presentations
Depression in adults with a chronic physical health problem
Advertisements

Nursing Care of Patients WithUpper GI Disturbances
Laparoscopic Placement of Gastric Electro Stimulator
Understanding Gastroparesis Enterra ® Therapy. 2 Anatomical Overview.
Enterra ® Therapy N’vision ® Programmer. 2 | MDT Confidential N’Vision: Therapy Management easy to use and transport programming efficiency reduces the.
429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.
Enterra® Therapy Overview.
Martha J. Morrell MD NeuroPace, Inc.
Peptic ulcer disease.
Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of.
Clinical Trials Medical Interventions
Oesophageal Cancer. -improving outcomes. Anil Kaul Consultant General and Upper GI Surgery St Helens and Knowsley Teaching Hospitals NHS Trust.
IRB PRESENTATION REGULATORY PATHWAYS HDE – PMA William Hellenbrand MD Director – Pediatric Cardiology Columbia University College of Physicians & Surgeons.
Gastrointestinal Surgery for Severe Obesity Prepared By: Dr. Fahad Al-Jindan Dr. Fahad Al-Jindan.
1.03 Healthcare Trends.
WHAT IS IVF? In vitro fertilization (IVF) is a process by which egg cells are manually fertilized by sperm outside of the womb. IVF is a major treatment.
Spinal Cord Stimulators in Neuropathic Pain. Introduction Chronic pain is very common Immense physical, psychological, societal impact Financial burden.
Overview of Neurostimulation
David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.
Advances in Gastroparesis Dmitry Oleynikov M.D, F.A.C.S Associate Professor of Surgery Joseph and Richard Still Faculty Fellow in Medicine Director of.
The Nature of Disease.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Session 8: Nutrition Care and Support of Adults Living with HIV.
Raneen Omary. Contents Definition Pathogenesis Epidemiology Acute Radiation Enteritis Chronic Radiation Enteritis Risk Factors Diagnosis DD Medical Management.
1.03 Healthcare Trends Understand healthcare agencies, finances, and trends Healthcare Trends Technology Epidemiology Geriatric Care Wellness Cost.
Dyspepsia MAHSA KHODADOOSTAN-- GASTROENTROLOGIST.
Digestive Disorders. Crohn’s Disease Chronic inflammatory bowel disease. Most common in small/large intestine. Causes: –Possible hereditary link to autoimmune.
This presentation has been created for colorectal surgeons who implant InterStim to discuss the therapy with referring clinician groups.
U.S. Neurostimulation Markets Leveraging CRM Technology for Treating Neurological Conditions “Until recently, the only modes of treatment for many neurological.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Gastroparesis Edmond Tai, Kar Yi Lim, Vivian Lin, Chan Park.
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
Introduction.
Investigational Devices and Humanitarian Use Devices June 2007.
FUNCTIONAL DYSPEPSIA H Ali Djumhana.
Purpose of Clinical Trials Assess safety and efficacy of Experimental treatments New combinations of drugs New approaches to surgery or radiation therapies.
Approch to dyspepsia Vossoughinia H Associate professor of medicine Mashad university of medical sceinces.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
POWERPOINT PRESENTATION Group Members- Labiba Sharmin Hossain ( ) Marvia Nabi Ratree ( )
INTERSTIM ® THERAPY for Urinary Control. What are Bladder Control Problems? Broad range of symptoms –May leak small or large amount of urine –May leak.
CONSIDERATIONS FOR SURGICAL MEDICAL DEVICE TRIALS LCTU Liverpool Clinical Trials Unit Considerations for Medical Device Trials.
Understanding Your Gastroesophageal Reflux Disease (GERD)
a revolutionary weight loss device
FUNCTIONAL (NON-ULCER) DYSPEPSIA TUCOM Internal Medicine 4th class Dr
Management Trichobezoar and Rapunzel syndrome in Children
Stomach cancer.
Palliative Care in MND Barry Laird Clinician Scientist in Palliative Medicine, University of Edinburgh and PRC Consultant in Palliative Medicine, St Columba’s.
DYSPEPSIA Dr.Azam teimouri Gastroenterologist
Division of Cardiovascular Devices
Chronic Complications of Diabetes in Surgery
Industry Perspective: Expanded Access Programs
1.03 PP3 Healthcare Trends.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Clinical Trials Medical Interventions
Success of a repeated tined lead trial in a refractory OAB population
1.03 Healthcare Trends.
1.03 Healthcare Trends.
1.03 Healthcare Trends.
Clinical Trials.
Medical Devices Maria P. Gonzalez Puente
Connor Elliott and Clark Hammer Tuesday, March 27, 2018 SNC2D Period B
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Care of Patients with Esophageal Problems
Supported in part by Arkansas Blue Cross and Blue Shield
1.03 Healthcare Trends.
1.03 Healthcare Trends.
1.03 Healthcare Trends.
New Models of Care in Idiopathic Pulmonary Fibrosis
Presentation transcript:

Enterra® Therapy Partnering for Gastric Health Expanding Options for Treating Gastroparesis Symptoms

Welcome <Insert name(s) of physician presenter(s), practice name/logo, physician photo(s)> <Insert information about therapies, treatments, procedures, and services provided at physician practice>

Agenda Overview of Gastroparesis What is it? Patient Quality of Life Typical Treatment Options Introduction to Gastric Electric Stimulation History Pacing vs Neurostimulation Enterra® Therapy System Practice Management Collaboration

What is Gastroparesis? Definition Gastroparesis is a stomach disorder in which food is digested more slowly than normal. With gastroparesis, the stomach muscles work poorly (or not at all), thus preventing the stomach from emptying properly. For some people, this condition results in serious nausea and vomiting that cannot be adequately controlled with standard medications. Symptoms Nausea Vomiting Abdominal bloating Abdominal pain Early satiety Heartburn or gastroesophageal reflux disease (GERD) Changes in blood sugar levels Lack of appetite Excessive weight loss/gain

What is Gastroparesis? Etiologies In a study of 146 patients, the most common origins were*: Idiopathic (35.6%) Diabetic (29%) Others (35.4%) *Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43(11)

What is Gastroparesis? Impact The impact of gastroparesis on physical well-being can be devastating. It can cause chronic nausea and vomiting and lead to malnutrition and inadequate blood sugar levels. Living with gastroparesis also affects emotional well-being – the constant discomfort of chronic nausea and vomiting can affect school and work performance, family and personal relationships, and social activities. Diagnosis Diagnosis is based on a complete medical history, physical examination, and tests that may include: Upper gastrointestinal endoscopy Gastric emptying test (GET) Gastroduodenal manometry Electrogastrography (EGG)

Treatment Options for Gastroparesis There is no cure for gastroparesis but there are treatment options that can control the symptoms of chronic vomiting and nausea. Often, multiple therapies are used in combination*. An overview of care for gastroparesis includes: *Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18(4):263-28

Gastric Electrical Stimulation ENTERRA THERAPY What’s Next for Gastroparesis Patients? My practice can offer an option for your patients who aren’t responding favorably to their existing regimen. Gastric Electrical Stimulation ENTERRA THERAPY

Gastric Stimulation Program History 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 … 2014 1st Clinical Case Study Animal Study, U. Tenn GEMS Multicenter Feasib. Trial Gastric Emptying Study U VA Pacing Studies WAVESS Trial Compassionate Use CUESS Gastric HUD/HDE US Therapy Launch (DDW) 100 US Implants US RCT European Launch 500 US Implants 1000 US Implants 1500 US Implants 8000 US Implants 2009 9

History of Gastric Electrical Stimulation 1963 Bilgutay et al.- The concept of electrical stimulation started when gastric stimulation was practiced for the treatment of postoperative ileus.

Pacing vs. Neurostimulation Gastric pacing is a commonly used phrase for gastric electrical stimulation (GES). Enterra® Therapy utilizes gastric electrical stimulation or neurostimulation. Neurostimulation is an activation of a nausea and vomiting control mechanism, utilizing a high-frequency, low-energy stimulation to achieve symptomatic relief Pacing is an application of an electrical stimulus that activates contraction of gastric smooth muscle, entraining at the rate of the intrinsic slow wave by a low-frequency, high-energy method

Gastric Pacing vs. Neurostimulation  Neurostimulation: Frequency > Intrinsic Low Energy Energy Frequency Pacing: Frequency ~ Intrinsic High Energy 

Enterra Therapy for Gastroparesis Enterra Therapy with gastric electrical stimulation (GES) is an innovative approach to treating patients with chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of idiopathic or diabetic origin. The therapy uses mild electrical pulses to stimulate the nerves of the antrum. This stimulation may reduce the symptoms of nausea and the number of vomiting episodes related to gastroparesis.* Introduced by Medtronic, Inc., the world leader in implantable medical technologies, Enterra Therapy can be turned off or removed if there is no longer a benefit. *Abell T, McCallum R, Hocking M, et al. Gastric electrical stimulation for medically refractory gastroparesis. Grastroenterology. 2003; 125(2):421-428

The Enterra System

Enterra Therapy U.S. Indication “Enterra Therapy is indicated for the treatment of patients with chronic, intractable (drug-refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic origin in patients aged 18 to 70 years.” Designated as Humanitarian Use Device (HUD) September 23, 1999 by the FDA Approved as Humanitarian Device Exemption (HDE) March 31, 2000 by the FDA

FDA Approval of Humanitarian Device Exemption Enterra Therapy for Gastric Electrical Stimulation has been approved by the FDA under a Humanitarian Device Exemption (HDE)* for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology. A Humanitarian Use Device is an FDA classification covering medical devices for the treatment of conditions affecting fewer than 4,000 new patients per year. The FDA reviewed the safety of the device and determined that the probable health benefits outweigh the risks of injury or illness from its use. Efficacy of treatment, however, has not been established by large clinical trials. Surgery to implant Enterra Therapy for Gastric Electrical Stimulation can only be performed in medical centers that specifically approve its use and have institutional review board (IRB) approval. *Humanitarian Device: The effectiveness of this device for the treatment of Gastric Electrical Stimulation has not been established.

Practice Management Collaboration Specialist/Implanter Referring Physician Collaborative Process to Optimize Patient Care Initial Diagnosis Behavioral Therapies Referral Further Diagnostics Enterra Implant Device-related Follow-up Ongoing General Patient Care

Trust the Experience of Medtronic Neuromodulation Therapies OCD1 Parkinson’s Disease Essential Tremor Chronic Pain Gastroparesis1 Bladder Control and Bowel Control Dystonia1 Severe Spasticity 1Humanitarian Device Exemption (HDE): The effectiveness of these devices has not been demonstrated.

Key Patient Selection Criteria Physician weighs all available treatment options evaluates appropriate patients educates patient and family about therapy and expectations discusses surgical procedure of Enterra Therapy with patient and family defines follow-up schedule and expectations Patient Idiopathic or diabetic gastroparesis Chronic, severe vomiting or nausea Drug-refractory

Adverse Events Enterra Therapy has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. In addition to risks related to a medical procedure, adverse events related to the system may include: Infection Pain at the implant site Lead penetration Bowel obstruction or perforation Programming difficulty Undesirable change in stimulation Lead entanglement or erosion Irritation/inflammation over the implant site Device mechanical or electrical problems Any of these may require additional surgery or cause return of symptoms. Additional information on Enterra Therapy is available at www.enterratherapy.com.

Benefits of Referring Your Patients Manage treatment options for your Gastroparesis patients Specialized training and education in gastric electrical stimulation Extensive experience with leading-edge technology and interventions related to neuromodulation Collaborate to develop a follow-up plan once symptoms are successfully treated

Summary Gastroparesis is very rare and debilitating disease and significantly impacts a person’s health and quality of life. Patients are often unaware of the various treatment options available. If conservative treatments have been unsuccessful, refer patients to a specialist for alternative treatment options. By partnering with a specialist, treatment options can be expanded to help find the best solution to manage gastroparesis symptoms.

Important Safety Information